Trade

Watchlist

Portfolio

Message

Set Alert

BSE LIVE NSE LIVE 26 Aug, 2025 12:21 Volume Todays L/H More ×

Cipla is betting big on its partnership with Eli Lilly to commercialize tirzepatide, the blockbuster diabetes and weight-loss drug sold globally under the brand name Mounjaro, as it seeks to deepen access across India’s Tier 2 and Tier 3 towns.

Outgoing CEO Umang Vohra called the deal a “material product for Cipla,” underscoring the strategic importance of the tie-up with Lilly, which already sells the drug in India. Cipla will market the product under the brand name Yurpeak, leveraging its expansive distribution network and field force to reach underserved geographies.

“The purpose of what we’re trying to do is to take the product much deeper into India,”

See Full Page